From the Journals

Metformin’s Potential Role in PCO

Common diabetes therapy reaches intraocular lens tissue and may help limit posterior capsule opacification, says newly published data

Share

Recent research published in the British Journal of Ophthalmology suggests that metformin, a commonly prescribed antidiabetic drug, may help reduce the risk of posterior capsule opacification (PCO) in patients undergoing cataract surgery. PCO is a frequent complication affecting up to 30% of patients post-surgery. In a study involving 20 patients with type 2 diabetes, metformin was found to concentrate in the lens capsule, correlating with serum levels. In vitro tests also demonstrated that metformin attenuates LEC proliferation, providing insight into the protective role of metformin against PCO.

Original Source(s)

Metformin’s Potential Role in PCO

Common diabetes therapy reaches intraocular lens tissue and may help limit posterior capsule opacification, says newly published data

  • by Conexiant News Staff

  • March 5, 2026

  • 3 min

Related Content

Patterns of Spread in Ocular Melanoma

Study examines lymphatic and distant metastasis risk

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Boris Malyugin: Power List Perspectives

Our Power Lister winners explore the major trends in their field, and the seismic impact AI and machine learning is having on the profession